8-K: Tivic Health Appoints Permanent CFO, Expands Equity Plan, and Secures Stockholder Approval for Key Issuances

Tivic Health Systems, Inc. announced the appointment of Lisa Wolf as permanent Chief Financial Officer, the transition of its Chief Scientific Officer to a consultant role, and stockholder approval of an amended equity incentive plan and several significant stock issuances.

Summary

• Lisa Wolf has been appointed as Tivic Health Systems, Inc.'s permanent Chief Financial Officer, effective July 7, 2025, transitioning from her interim consultant role since October 2024.
• As permanent CFO, Ms. Wolf will receive a base salary of $240,000 per annum and is eligible for an annual incentive bonus of up to 35% of her base salary, along with potential annual focal equity grants.
• Blake Gurfein stepped down as Chief Scientific Officer, effective July 4, 2025, to pursue other opportunities, but will continue to provide part-time consulting services for at least six months at $20,000 per month, focusing on the vagus nerve stimulation program.
• Dr. Gurfein will receive a lump sum cash payment of $45,938 and his unvested equity awards will continue to vest during his consultancy.
• Stockholders approved an amendment to the 2021 Equity Incentive Plan, increasing the number of shares authorized for issuance by 425,000, bringing the total to 511,669 shares, effective June 30, 2025.
• At the Annual Meeting on June 30, 2025, stockholders elected Christina Valauri as a Class I director, ratified Rosenberg Rich Baker Berman, P.A. as the independent accounting firm, and approved several common stock issuances related to agreements with Statera Biopharma, Inc., a Securities Purchase Agreement investor, and Mast Hill Fund, L.P.

Sentiment

Score: 7

Explanation: The document reflects positive corporate governance and strategic steps, including securing a permanent CFO, retaining a key scientific expert as a consultant, and successfully obtaining stockholder approval for equity plan expansion and capital-raising related share issuances. No negative financial performance or operational issues are disclosed.

Positives

• The appointment of Lisa Wolf as permanent Chief Financial Officer provides stability and continuity in a key executive role, leveraging her prior experience as interim CFO and in SEC reporting.
• Retaining Blake Gurfein as a consultant ensures continued expertise and support for the critical vagus nerve stimulation program, mitigating the impact of his departure as CSO.
• Stockholder approval of the 2021 Equity Incentive Plan amendment, increasing authorized shares by 425,000, enhances the company's ability to attract and retain talent through equity compensation.
• All proposals presented at the Annual Meeting, including significant stock issuances related to strategic agreements and financing, received stockholder approval, indicating strong support for the company's strategic direction and capital-raising efforts.

Negatives

• Blake Gurfein, a key executive, stepped down as Chief Scientific Officer, which could represent a loss of leadership, despite his transition to a consulting role.
• The CFO's employment is at-will, a standard practice but means either party can terminate employment at any time without cause, potentially impacting executive stability.

Risks

• Lisa Wolf's employment is at-will, meaning either she or the company can terminate employment at any time and for any reason, with or without cause.
• Lisa Wolf will not be entitled to an annual end-of-year incentive bonus if her employment terminates for any reason before December 31 of a given year.
• Severance benefits for Lisa Wolf are conditional upon an 'Involuntary Termination' (termination by company without cause or resignation for good reason) and require the execution and non-revocation of a waiver and release of claims agreement.
• The continued vesting of Blake Gurfein's unvested equity awards is contingent upon his continued provision of services as a consultant, which is for a period of no less than six months, introducing a potential future discontinuity.

Future Outlook

The company anticipates granting an equity incentive award to Lisa Wolf in line with similarly situated executives. Blake Gurfein will continue to support the development of the vagus nerve stimulation program as a consultant for at least six months. The 2021 Equity Incentive Plan includes automatic annual increases in authorized shares, providing ongoing flexibility for future equity grants.

Management Comments

• Dr. Gurfein's decision to step down was not based on any disagreement with the company on any matter relating to its operations, policies or practices.

Industry Context

This announcement reflects standard corporate governance and executive management activities within the medical device or biotechnology sector, where companies frequently adjust leadership roles, manage equity compensation plans, and seek stockholder approvals for financing-related share issuances to support ongoing operations and strategic initiatives, such as the development of specific programs like vagus nerve stimulation.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential dilution from the increased authorized shares for the equity plan and the approved stock issuances related to financing and partnerships. However, they benefit from strengthened management with a permanent CFO and continued scientific expertise through the CSO's consulting role.
• Employees: Benefit from the expanded 2021 Equity Incentive Plan, which allows for more equity grants, potentially enhancing their compensation and aligning their incentives with company performance.
• Customers: No direct impact mentioned, but stable management and continued R&D (vagus nerve stimulation program) could indirectly benefit product development and service quality.
• Management: Lisa Wolf gains a permanent CFO role with a structured compensation package and equity eligibility. Blake Gurfein transitions to a flexible consulting role, maintaining a connection to the company's key programs while pursuing other opportunities.

Next Steps

• The Chief Executive Officer will recommend to the Board, at its next meeting, that Ms. Wolf be granted an equity incentive award.
• Lisa Wolf's annual base salary will be subject to review and adjustment based on the company's normal performance review practices.
• Lisa Wolf will be eligible for consideration for annual focal grants under the 2021 Equity Incentive Plan.
• Blake Gurfein will continue to provide part-time services to the company as a consultant for a period of no less than six months, aiding in the further development of the company's vagus nerve stimulation program.
• Blake Gurfein's outstanding unvested equity awards will continue to vest for so long as he continues to provide services to the company as a consultant.

Key Dates

Recommendation

Keywords

Tivic Health Systems, Chief Financial Officer, Chief Scientific Officer, SEC filing, 8-K, corporate governance, equity incentive plan, stock issuance, Nasdaq, annual meeting, stockholder approval, executive compensation, vagus nerve stimulation